Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells.

NASH - non-alcoholic steatohepatitis NK cells inflammation liver fibrosis monocyte-derived macrophage (MDM)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 31 05 2023
accepted: 04 03 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 19 4 2024
Statut: epublish

Résumé

Chronic liver diseases, such as non-alcoholic steatohepatitis (NASH)-induced cirrhosis, are characterized by an increasing accumulation of stressed, damaged, or dying hepatocytes. Hepatocyte damage triggers the activation of resident immune cells, such as Kupffer cells (KC), as well as the recruitment of immune cells from the circulation toward areas of inflammation. After infiltration, monocytes differentiate into monocyte-derived macrophages (MoMF) which are functionally distinct from resident KC. We herein aim to compare the

Identifiants

pubmed: 38638443
doi: 10.3389/fimmu.2024.1232070
pmc: PMC11025356
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1232070

Informations de copyright

Copyright © 2024 Sauer, Steixner-Kumar, Gabler, Motyka, Rippmann, Brosa, Boettner, Schönberger, Lempp, Frodermann, Simon, Krenkel and Bahrami.

Déclaration de conflit d'intérêts

Author MM is employed by the company Ardigen. Authors JS, AS-K, SG, JR, SB, DB, TS, CL, VF, ES, OK, and EB are employed by the company Boehringer Ingelheim.

Références

Front Immunol. 2018 Dec 14;9:2948
pubmed: 30619308
JHEP Rep. 2022 Feb 01;4(4):100444
pubmed: 35252828
BMC Cancer. 2018 Sep 18;18(1):899
pubmed: 30227835
Gastroenterology. 2015 Dec;149(7):1896-1909.e14
pubmed: 26344055
Mol Med Rep. 2022 Jun;25(6):
pubmed: 35506449
Gut. 2014 Dec;63(12):1960-1971
pubmed: 24561613
Cell. 2022 Jan 20;185(2):379-396.e38
pubmed: 35021063
Sci Transl Med. 2020 Dec 2;12(572):
pubmed: 33268509
Cell. 2019 Jul 25;178(3):686-698.e14
pubmed: 31257031
PLoS One. 2010 Jun 10;5(6):e11049
pubmed: 20548789
J Hepatol. 2022 Nov;77(5):1373-1385
pubmed: 35750138
Nat Commun. 2016 Jan 27;7:10321
pubmed: 26813785
Nat Rev Immunol. 2022 Jul;22(7):429-443
pubmed: 34741169
Gut. 2012 Mar;61(3):416-26
pubmed: 21813474
J Leukoc Biol. 2019 Apr;105(4):695-704
pubmed: 30748035
J Exp Med. 2020 Feb 13;217(3):e20190103
pubmed: 32997468

Auteurs

Julia Sauer (J)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Agnes A Steixner-Kumar (AA)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Svenja Gabler (S)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Maciej Motyka (M)

Ardigen S.A., Cracow, Poland.

Jörg F Rippmann (JF)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Stefan Brosa (S)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Dennis Boettner (D)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Tanja Schönberger (T)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Charlotte Lempp (C)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Vanessa Frodermann (V)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Eric Simon (E)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Oliver Krenkel (O)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Ehsan Bahrami (E)

Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Classifications MeSH